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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S482joint lavage, so aspirate composition likely reﬂects disease state and/or
response to IA treatments. Other factors including joint loading, activity
level, and inﬂammation may also inﬂuence SF lubricant composition
over time. As such, the present study suggests that boundary lubricant
composition of SF in OA joints can change over time with repeated IA
treatment, and that this response to IA CST or HA treatment appears to
vary between individuals. IA PRG4 has been shown to stimulate
endogenous production of PRG4 in preclinical models, and PRG4 can
affect boundary lubricating and rheological properties of HAþPRG4
solutions and SF in vitro. Furthermore, PRG4 concentrations appear to
be decreased in some chronic OA patients, suggesting that future study
of IA PRG4HA is warranted and could provide further insight into the
mechanism of action of IA HA(PRG4) biotherapeutic treatments. The
outcome of such future analysis of SF lubricant composition, boundary
lubricating function, and pain relief provided by IA PRG4HA might
ultimately be beneﬁcial for chronic, symptomatic OA patients with
compromised SF boundary lubricant composition.
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FULL-THICKNESS CARTILAGE DEFECTS REPAIR WITH
MICROFRACTURE TECHNIQUE AND INTRA-ARTICULAR INJECTION
OF A SMALL MOLECULE COMPOUND KARTOGENIN
X. Xu, Y. Shen, D. Shi, Q. Jiang. Sports Med. and Adult Reconstruction,
Nanjing, China
Purpose: To evaluate the outcome of . Methods: Full-thickness cartilage
defects were created in patellar groove of both femurs in 24 female New
Zealand White rabbits. The defects were then performed microfracture
surgery. The animals were divided into two groups according to post-
operative treatment. 12 rabbits were treated with intra-articular
injection of kartogenin (KGN) for once a week (Group A); the other 12
rabbits were treated with intra-articular injection of DMSO for once a
week (Group B). Animals were scariﬁced at 1 and 3months after
injection. 6 rabbits from each group at every time interval were killed
and the knees were harvested. The defects repair was assessed byMacroscopic, hematoxylin and eosin staining, toluidine blue staining,
and immunohistochemical stain for collagen type II. Differences
between groups at each time point were analyzed.
Results: 1month after treatment, no signiﬁcant differencewas detected
between Group A and Group B. After 3 months’ weekly injection, Group
A showed signiﬁcantly better macroscopic view, quality of repair tissue
and lateral integration than Group B.
Conclusions: 3 months’ intra-articular injection of KGN after
microfracture signiﬁcantly improve the effectiveness of treatment




THE S100A9 INHIBITOR PAQUINIMOD (ABR-215757) REDUCES
SYNOVIAL ACTIVATION, OSTEOPHYTE FORMATION AND CARTILAGE
DAMAGE IN EXPERIMENTAL OSTEOARTHRITIS
R.F. Schelbergen y, A.B. Blom y, T. Leanderson z, H. Eriksson x,
W.B. van den Berg y, P.M. van der Kraan y, P.L. van Lent y. yRadboud Univ.
Med. center, Nijmegen, Netherlands; z Lund Univ., Lund, Sweden; xActive
Biotech AB, Lund, Sweden
Purpose: Synovial activation is present in a large subset of osteo-
arthritis (OA) patients and it is thought to play an important role in the
development of OA pathology. Previously, we found that activated
macrophage products S100A8 and S100A9 are involved in cartilage
degradation and synovial activation during experimental OA. Paquini-
mod is a quinoline-3-carboxamide compound with immunomodula-
tory properties that is currently in clinical development for treatment of
systemic sclerosis. It targets the S100A9 protein and blocks the binding
of S100A9 to RAGE and TLR-4.In the current study we investigated the
effect of the S100A9-blocking compound paquinimod on experimental
osteoarthritis with different degrees of synovial activation.
Methods: Collagenase induced OA (CIOA) was induced by two times
intra-articular injection of 1U collagenase and DMM was induced by
transsection of the medial anterior meniscotibial ligament leading to
destabilization of the medial meniscus (DMM), both in C57Bl6 mice.
Paquinimod (3,75 mg/kg) was administered in the drinking water 4
days before induction of OA in both CIOA and DMM and refreshed
twice a week. Whole knee joints were isolated and embedded in
parafﬁn for histological sectioning. Synovial thickening and cellu-
larity was measured using an arbitrary score from 0-3. OA-like car-
tilage pathology was scored using a modiﬁed Pritzker OARSI score.
Osteophyte size was measured by a blinded observer using image
analysis software.
Results: First, we assessed the effect of paquinimod on DMM devel-
opment on day 56. Synovial activation in this surgical model is low, as
are S100A8/A9 levels in the synovium. No differences were observed on
osteophyte size between paquinimod-treated and non-treated animals
at both medial tibia and medial femur. Furthermore, OA-like cartilage
pathology was only signiﬁcantly reduced by paquinimod-treatment at
